



NDA 209884

NDA APPROVAL

Novartis Pharmaceuticals Corporation
Attention: Mercy Abraham, Pharm.D.
Senior Global Program Regulatory Manager
One Health Plaza, Mailstop: # 310/2150F
East Hanover, NJ 07936-1080

Dear Dr. Abraham:

Please refer to your New Drug Application (NDA) dated and received July 26, 2018, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Mayzent (siponimod) tablets.

This new drug application provides for the use of Mayzent (siponimod) tablets for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Medication Guide) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*, available at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the carton and container labeling submitted on March 22, 2019, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (April 2018, Revision 5)*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved NDA 209884.**” Approval of this submission by FDA is not required before the labeling is used.

ADVISORY COMMITTEE

Your application for Mayzent (siponimod) was not referred to an FDA advisory committee because this drug is not the first in its class, the safety profile is similar to that of other drugs approved for this indication, the clinical trial design was acceptable, the efficacy findings were clear, and the safety profile was acceptable in light of the serious nature of the disease being treated.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for ages birth up to 10 years because necessary studies are impossible or highly impracticable. This is because of the small number of patients in this age group with relapsing forms of multiple sclerosis.

We are deferring submission of your pediatric studies for ages 10 up to 17 years for this application because this product is ready for approval for use in adults and the pediatric studies have not been completed.

Your deferred pediatric studies required by section 505B(a) of the FDCA are required postmarketing studies. The status of this/these postmarketing studies must be reported annually according to 21 CFR 314.81 and section 505B(a)(4)(C) of the FDCA. These required studies are listed below.

3591-1 Juvenile rat toxicology study to evaluate effects of siponimod on growth, reproductive development, and neurological and neurobehavioral development.

Draft Protocol Submission: 07/18

Final Protocol Submission: 04/19

Study/Trial Completion: 08/19
Final Report Submission: 02/20

3591-2 Conduct a two-part study of siponimod in pediatric patients with relapsing forms of multiple sclerosis (RMS) at least 10 years and less than 18 years of age. Part A is an open-label study of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of siponimod in pediatric patients. Part A will include two cohorts, one with body weights less than 40 kg and the other with body weights 40 kg or more. The objective of Part A is to determine titration and maintenance doses of siponimod that will result in PK and PD effects that are comparable to those of the 5-day titration and the 1- or 2-mg genotype-based maintenance doses administered to adult patients. Part B is a randomized, double-blind, parallel-group study to evaluate the efficacy and safety of siponimod compared to an appropriate control.

Draft Protocol Submission: 03/20
Final Protocol Submission: 09/20
Study/Trial Completion: 09/25
Final Report Submission: 03/26

Submit the protocols to your IND 76122 with a cross-reference letter to this NDA.

Reports of these required pediatric postmarketing studies must be submitted as a new drug application (NDA) or as a supplement to your approved NDA with the proposed labeling changes you believe are warranted based on the data derived from these studies. When submitting the reports, please clearly mark your submission "**SUBMISSION OF REQUIRED PEDIATRIC ASSESSMENTS**" in large font, bolded type at the beginning of the cover letter of the submission.

POSTMARKETING REQUIREMENTS UNDER 505(o)

Section 505(o)(3) of the FDCA authorizes FDA to require holders of approved drug and biological product applications to conduct postmarketing studies and clinical trials for certain purposes, if FDA makes certain findings required by the statute.

We have determined that an analysis of spontaneous postmarketing adverse events reported under subsection 505(k)(1) of the FDCA will not be sufficient to assess a known serious risk of pulmonary toxicity or identify an unexpected serious risk of teratogenicity.

Furthermore, the new pharmacovigilance system that FDA is required to establish under section 505(k)(3) of the FDCA will not be sufficient to assess these serious risks.

Therefore, based on appropriate scientific data, FDA has determined that you are required to conduct the following studies:

- 3591-3 A prospective, parallel cohort study in patients with relapsing forms of multiple sclerosis to assess the potentially serious risk of pulmonary toxicity. The two cohorts should consist of patients newly prescribed siponimod and patients receiving another drug used to treat relapsing forms of multiple sclerosis. The study design should minimize differences between the cohorts by defining the populations in both cohorts so that they will be similar, by ensuring that both cohorts have similar clinical assessments (specifically FEV1, FVC, and DLCO), and by ensuring that patients who discontinue treatment have continued follow-up. In addition, the study protocol should account for duration of exposure, treatment changes, and loss to follow-up. Sample size should be supported by estimates of the rates of the events of interest.

The timetable you submitted on March 19, 2019, states that you will conduct this study according to the following schedule:

Draft Protocol Submission:	06/20
Final Protocol Submission:	12/20
Study Completion:	12/26
Final Report Submission:	12/27

- 3591-4 Conduct prospective pregnancy exposure registry cohort analyses in the United States that compare the maternal, fetal, and infant outcomes of women with multiple sclerosis exposed to siponimod during pregnancy with two unexposed control populations: one consisting of women with multiple sclerosis who have not been exposed to siponimod before or during pregnancy, and the other consisting of women without multiple sclerosis. The registry will identify and record pregnancy complications, major and minor congenital malformations, spontaneous abortions, stillbirths, elective terminations, preterm births, small for gestational-age births, and any other adverse outcomes, including postnatal growth and development. Outcomes will be assessed throughout pregnancy.

Infant outcomes, including effects on postnatal growth and development, will be assessed through at least the first year of life.

The timetable you submitted on March 21, 2019, states that you will conduct this study according to the following schedule:

Draft Protocol Submission:	03/20
Final Protocol Submission:	09/20
Annual Interim Report Submissions:	09/21
	09/22
	09/23
	09/24
	09/25
	09/26
	09/27
	09/28
	09/29
	09/30
Study Completion:	09/31
Final Report Submission:	09/32

3591-5 Conduct a pregnancy outcomes study using a different study design than provided for in PMR 3591-4 (for example, a retrospective cohort study using claims or electronic medical record data or a case control study) to assess major congenital malformations, spontaneous abortions, stillbirths, and small-for-gestational-age births in women exposed to siponimod during pregnancy compared to an unexposed control population.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.